Nuveen Asset Management LLC Purchases 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Nuveen Asset Management LLC increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,807,420 shares of the biopharmaceutical company's stock after acquiring an additional 159,139 shares during the quarter. Nuveen Asset Management LLC owned about 1.27% of Amicus Therapeutics worth $35,866,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Wellington Management Group LLP grew its position in Amicus Therapeutics by 18.8% in the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after purchasing an additional 4,497,950 shares during the last quarter. Norges Bank bought a new stake in shares of Amicus Therapeutics in the 4th quarter worth about $29,033,000. Orbimed Advisors LLC increased its holdings in shares of Amicus Therapeutics by 300.7% during the fourth quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock worth $21,528,000 after buying an additional 1,715,100 shares in the last quarter. Rock Springs Capital Management LP raised its stake in shares of Amicus Therapeutics by 107.9% in the fourth quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company's stock valued at $24,487,000 after acquiring an additional 1,349,145 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Amicus Therapeutics by 174.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company's stock worth $19,863,000 after acquiring an additional 1,339,316 shares in the last quarter.

Amicus Therapeutics Trading Down 0.6%

Shares of FOLD traded down $0.04 during trading hours on Monday, reaching $6.22. The stock had a trading volume of 2,822,292 shares, compared to its average volume of 2,840,115. Amicus Therapeutics, Inc. has a 52 week low of $5.81 and a 52 week high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The company has a market cap of $1.92 billion, a P/E ratio of -34.56, a P/E/G ratio of 1.51 and a beta of 0.64. The firm has a 50-day moving average of $7.11 and a 200 day moving average of $8.71.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on FOLD shares. Wells Fargo & Company dropped their price target on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. UBS Group increased their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. The Goldman Sachs Group dropped their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Finally, Wall Street Zen lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.